About natureza

This author has not yet filled in any details.
So far natureza has created 18 blog entries.

Natureza Presents New Antibiotic Agents at Conference on Drug Development

Preclinical evaluation of a novel membrane-intercalating agent shows antibacterial activity with no generation of bacterial resistance. Membrane fluidity is key to the function of prokaryotic and eukaryotic cells. Natureza Products, Inc has developed chitosan-coated esters of dodecanoic acid as membrane intercalating agents with anti-inflammatory and antibacterial properties. These can be targeted to Gram-positive or negative bacteria by alteration of charge and decoration on the chitosan coat, and bacteria show no innate or evolved resistance to these agents on exposure. [read more]

Natureza Presents New Antibiotic Agents at Conference on Drug Development2022-10-12T17:00:42+00:00

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

Bacterial antimicrobial resistance (AMR)—which occurs when changes in bacteria cause the drugs used to treat infections to become less effective—has emerged as one of the leading public health threats of the 21st century. The Review on Antimicrobial Resistance, commissioned by the UK Government, argued that AMR could kill 10 million people per year by 2050. [read more]

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis2022-10-03T22:13:51+00:00

Natureza Patents New Antibiotic Agents

Natureza’s research offers a true paradigm shift, one that would remove the imbalance in development cost by eliminating the ability of bacteria to become resistant. With the promise of new drugs being able to be marketed for years providing not only the time to recover investment, but a profit as well, a new investment environment would emerge that would encourage the development of new, much needed antibiotics. [read more]

Natureza Patents New Antibiotic Agents2022-10-03T22:08:53+00:00

Lack of new antibiotics threatens global efforts to contain drug-resistant infections.

Declining private investment and lack of innovation in the development of new antibiotics are undermining efforts to combat drug-resistant infections, says the World Health Organization (WHO). Two new reports reveal a weak pipeline for antibiotic agents. The 60 products in development (50 antibiotics and 10 biologics) bring little benefit over existing treatments and very few target the most critical resistant bacteria (Gram-negative bacteria). [read more]

Lack of new antibiotics threatens global efforts to contain drug-resistant infections.2022-09-22T15:24:50+00:00

WHO to World: The Foundation of Modern Medicine is Crumbling

The WHO has recognised a number of antibiotic-resistant pathogens as posing the greatest threat to human health. It further concluded that mortality and morbidity from resistant infections is on the rise globally, the clinical anti-bacterial pipeline remains insufficient, and the pipeline outlook remains bleak (WHO 2019). [read more]

WHO to World: The Foundation of Modern Medicine is Crumbling2022-10-03T22:17:04+00:00

The Truly Staggering Cost Of Inventing New Drugs

During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs between $4-$11 billion. [read more]

The Truly Staggering Cost Of Inventing New Drugs2022-09-22T15:15:59+00:00

Opinion: We Need More than New Antibiotics to Fight Resistance

Metabolic disrupters, phages, and other approaches are going to be needed to treat the broadest possible range of patients infected by bacterial pathogens resistant to multiple drugs. In 1924 President Coolidge's youngest son developed a blister on a toe playing tennis. The blister became infected with staph, and he died a week later at just 16 years old. Two decades later, penicillin could have saved him, but this drug is now useless against staph because of drug resistance, which has now become a broader crisis in medicine. [read more]

Opinion: We Need More than New Antibiotics to Fight Resistance2022-09-22T15:18:10+00:00

Antibiotic Resistance: A Rundown of a Global Crisis

The advent of multidrug resistance among pathogenic bacteria is imperiling the worth of antibiotics, which have previously transformed medical sciences. The crisis of antimicrobial resistance has been ascribed to the misuse of these agents and due to unavailability of newer drugs attributable to exigent regulatory requirements and reduced financial inducements. [read more]

Antibiotic Resistance: A Rundown of a Global Crisis2022-09-22T15:23:20+00:00

The Rise of Superbugs: Facing the Antibiotic Resistance Crisis

While medical research has helped us overcome many health threats, we now face a new type of crisis: Many dangerous bacteria are becoming resistant to the drugs meant to fight them. Healthcare professionals antibiotics to treat many forms of bacterial infection — from those that are mild to those that are potentially life threatening. For the most part, antibiotics have proved to be a crucial ally in the fight for health, but over the past few years, these drugs have begun to lose their footing in their confrontation with bacteria. [read more]

The Rise of Superbugs: Facing the Antibiotic Resistance Crisis2022-09-22T15:28:26+00:00
Go to Top